Literature DB >> 1968483

Nosocomial outbreaks due to amikacin-resistant tobramycin-sensitive Acinetobacter species: correlation with amikacin usage.

Y Buisson1, G Tran Van Nhieu, L Ginot, P Bouvet, H Schill, L Driot, M Meyran.   

Abstract

Fifty-seven patients in the Val-de-Grâce hospital were infected or colonized with amikacin-resistant, tobramycin-sensitive Acinetobacter spp. between January 1985 and December 1987. This resistance phenotype was attributed to the recently described 3'-O-aminoglycoside phosphotransferase (APH(3')-VI), on the basis of substrate profile and DNA-DNA hybridization, and was mainly encountered in various biotypes of A. baumannii isolated from patients. It was also encountered in saprophytic A. johnsonii isolates from the hands of 11 healthy workers among the medical staff, which provided evidence for the dissemination of an epidemic gene among different biotypes and species of Acinetobacter. A retrospective epidemiological survey showed a significant correlation between amikacin consumption and case incidence in the wards where cross-infection had occurred.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1968483     DOI: 10.1016/0195-6701(90)90024-i

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  15 in total

Review 1.  Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features.

Authors:  E Bergogne-Bérézin; K J Towner
Journal:  Clin Microbiol Rev       Date:  1996-04       Impact factor: 26.132

2.  Antimicrobial susceptibilities of clinical isolates of Acinetobacter baumannii from Singapore.

Authors:  B G Kuah; G Kumarasinghe; J Doran; H R Chang
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

3.  Survival of Acinetobacter baumannii on dry surfaces.

Authors:  C Wendt; B Dietze; E Dietz; H Rüden
Journal:  J Clin Microbiol       Date:  1997-06       Impact factor: 5.948

4.  Alterations in surface hydrophobicity of Acinetobacter baumannii induced by meropenem.

Authors:  A Hostacká
Journal:  Folia Microbiol (Praha)       Date:  1999       Impact factor: 2.099

5.  Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistant Acinetobacter baumannii.

Authors:  X Corbella; A Montero; M Pujol; M A Domínguez; J Ayats; M J Argerich; F Garrigosa; J Ariza; F Gudiol
Journal:  J Clin Microbiol       Date:  2000-11       Impact factor: 5.948

6.  Spread of amikacin resistance in Acinetobacter baumannii strains isolated in Spain due to an epidemic strain.

Authors:  J Vila; J Ruiz; M Navia; B Becerril; I Garcia; S Perea; I Lopez-Hernandez; I Alamo; F Ballester; A M Planes; J Martinez-Beltran; T J de Anta
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

7.  Epidemiological study of an Acinetobacter baumannii outbreak by using polymerase chain reaction fingerprinting.

Authors:  Y Gräser; I Klare; E Halle; R Gantenberg; P Buchholz; H D Jacobi; W Presber; G Schönian
Journal:  J Clin Microbiol       Date:  1993-09       Impact factor: 5.948

8.  Use of pulsed-field gel electrophoresis for investigation of hospital outbreaks of Acinetobacter baumannii.

Authors:  A Gouby; M J Carles-Nurit; N Bouziges; G Bourg; R Mesnard; P J Bouvet
Journal:  J Clin Microbiol       Date:  1992-06       Impact factor: 5.948

9.  Emergence of resistant isolates of Acinetobacter calcoaceticus- A. baumannii complex in a Spanish hospital over a five-year period.

Authors:  M I García-Arata; T Alarcón; M López-Brea
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-06       Impact factor: 3.267

10.  In vitro antimicrobial production of beta-lactamases, aminoglycoside-modifying enzymes, and chloramphenicol acetyltransferase by and susceptibility of clinical isolates of Acinetobacter baumannii.

Authors:  J Vila; A Marcos; F Marco; S Abdalla; Y Vergara; R Reig; R Gomez-Lus; T Jimenez de Anta
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.